Drugs / VP4896
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00231946 | Sep 2005 → ? | Alzheimer disease | Voyager Pharmaceutical Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VP4896 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00231946 ↗ |
| Known as | leuprolide acetate | “VP4896 (a novel formulation of leuprolide acetate)” NCT00231946 ↗ |
| Action | Inhibit | “binds to and inactivates GnRH receptors on the pituitary gland” NCT00231946 ↗ |